Education
About Us
Working with TipRanks
Follow Us
Nls Pharmaceutics Ltd (NLSP)
:NLSP
Total Valuation
NLS Pharmaceutics has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
NLS Pharmaceutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
NLS Pharmaceutics’s return on equity (ROE) is -1.41 and return on invested capital (ROIC) is -311.45%.
Return on Equity (ROE)-1.41
Return on Assets (ROA)-0.89
Return on Invested Capital (ROIC)-311.45%
Return on Capital Employed (ROCE)-3.11
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NLS Pharmaceutics is ―. NLS Pharmaceutics’s PEG ratio is -0.00011.
PE Ratio―
PS Ratio0.00
PB Ratio0.11
Price to Fair Value0.11
Price to FCF-0.04
Price to Operating Cash Flow-0.06
PEG Ratio-0.00011
Income Statement
In the last 12 months, NLS Pharmaceutics had revenue of 0.00 and earned -1.98M in profits. Earnings per share was -26.30.
Revenue0.00
Gross Profit-3.32K
Operating Income-4.38M
Pretax Income-1.98M
Net Income-1.98M
EBITDA-3.63M
Earnings Per Share (EPS)-26.30
Cash Flow
In the last 12 months, operating cash flow was -4.81M and capital expenditures -3.92K, giving a free cash flow of -4.82M billion.
Operating Cash Flow-4.81M
Free Cash Flow-4.82M
Free Cash Flow per Share-10.00T>
Dividends & Yields
NLS Pharmaceutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change-78.83%
50-Day Moving Average16.85
200-Day Moving Average18.93
Relative Strength Index (RSI)17.29
Average Volume (3m)―
Important Dates
NLS Pharmaceutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
NLS Pharmaceutics as a current ratio of 2.69, with Debt / Equity ratio of 0.00%
Current Ratio2.69
Quick Ratio2.69
Debt to Market Cap0.00
Net Debt to EBITDA0.46
Interest Coverage Ratio-29.20
Taxes
In the past 12 months, NLS Pharmaceutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NLS Pharmaceutics EV to EBITDA ratio is 0.41, with an EV/FCF ratio of 0.35.
EV to Sales0.00
EV to EBITDA0.41
EV to Free Cash Flow0.35
EV to Operating Cash Flow0.35
Balance Sheet
NLS Pharmaceutics has $3.07M in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.07M billion.
Cash & Marketable Securities$3.07M
Total Debt$0.00
Net Cash$3.07M
Net Cash Per Share$10.00T>
Tangible Book Value Per Share$18.68
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for NLS Pharmaceutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―